Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.
From the official U.S. FDA label for brimonidine tartrate, the active ingredient registered with NAFDAC.
relieves redness of the eye due to minor eye irritations
Redness reliever
if solution changes color or becomes cloudy
For external use only Do not use if solution changes color or becomes cloudy Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye condition worsens or persists for more than 3 days If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
If pregnant or breast-feeding, ask a health professional before use.
Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.
Brimosopt 0.2% Eye Drop contains Brimonidine Tartrate (0.2%), as eye drops, according to its NAFDAC registration record.
Yes. Brimosopt 0.2% Eye Drop is listed on the NAFDAC register under registration number A4-101222, and its registration is active as of 6 November 2026.
No WHO falsified or substandard medical product alert currently matches Brimosopt 0.2% Eye Drop in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number A4-101222, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
relieves redness of the eye due to minor eye irritations (Summarised from the official U.S. FDA label for brimonidine tartrate. Always follow your doctor or pharmacist.)
Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.